

The field of personalised cancer care has changed dramatically since the early days of Glivec and Herceptin. We're getting smarter at identifying mutations and quicker at developing therapies that target them. Yet resistance, side-effects and the rarity of many mutations continue to pose significant challenges. In this e-grandround, the co-director of MD Anderson's Khalifa Institute for Personalised Cancer Therapy presents the current state of knowledge and charts a way forward.

What do you think?

- Is the personalised treatment paradigm on track to deliver meaningful benefit to large numbers of patients?
- What has to happen to overcome the obstacles?

You can read the article [here](#) . Press the comment button at the end and share your views